Answers are grounded in this paper and cite their sources.
Background & Aims Particulate hepatitis B core antigen (HBcoreAg) is a potent immunogen used as a vaccine carrier platform. HBcoreAg produced in E. coli encapsidates random bacterial RNA ( b RNA). Using the heterologous protein-prime, viral-vector-boost therapeutic hepatitis B vaccine TherVacB , we compared the properties of different HBcoreAg forms. We explored how the content of HBcoreAg modulates antigen stability, immunogenicity, and antiviral efficacy. Methods b RNA was removed from HBcoreAg by capsid disassembly, followed by reassembly in the absence or presence of specific nucleic-acid-based adjuvants poly I:C or CpG. The morphology and structure of empty, b RNA-, and adjuvant-loaded HBcoreAg were monitored by electron microscopy and nuclear magnetic resonance spectroscopy. Empty, b RNA-containing, or adjuvant-loaded HBcoreAg was applied together with HBsAg and with or without a nucleic-acid-based external adjuvant within the TherVacB regimen in both wild-type and HBV-carrier mice. Results While HBcoreAg retained its structure upon b RNA removal, its stability and immunogenicity decreased significantly. Loading HBcoreAg with nucleic-acid-based adjuvants re-established stability of the capsid-like antigen. Immunization with poly I:C- or CpG-loaded HBcoreAg induced high antibody titers against co-administered HBsAg. When applied within the TherVacB regimen, they activated vigorous HBcoreAg- and HBsAg-specific T-cell responses in wild-type and HBV-carrier mice requiring a significantly lower dose of adjuvant compared to externally added adjuvant. Finally, immunization with adjuvant-loaded HBcoreAg mixed with HBsAg led to long-term control of persistent hepatitis B virus replication in the HBV-carrier mice. Conclusion Adjuvant-loaded HBcoreAg retained capsid integrity and stability, was as immunogenic in vivo as externally adjuvanted HBcoreAg requiring lower adjuvant levels, and supported immunity against co-administered, non-adjuvanted HBsAg. Thus, they represent a promising novel platform for vaccine development. Impact and implications Hepatitis B core antigen (HBcoreAg) recapitulates the capsid of the hepatitis B virus that hosts the viral genome. Produced recombinantly, it is not infectious but emerges as a potent immunogen in vaccine development. In this preclinical study, we show that loading HBcoreAg with defined nucleic-acid-based adjuvants on the one hand stabilizes the HBcoreAg with standardized capsid content and, on the other hand, efficiently promotes the immunity of HBcoreAg and a co-administered antigen, allowing to reduce adjuvant doses. Therefore, adjuvant-loaded HBcoreAg not only serves as an encouraging option for therapeutic hepatitis B vaccines, but also acts as an efficient adjuvant delivery system for other types of vaccines.
No takes yet. Share an insight, caveat, or question.
Su et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: